![Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology](https://molpharm.aspetjournals.org/content/molpharm/97/3/171/F1.large.jpg)
Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology
![Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology](https://www.futuremedicine.com/cms/10.2217/fca.15.79/asset/images/medium/figure1.gif)
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology
![Frontiers | A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers | Psychiatry Frontiers | A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers | Psychiatry](https://www.frontiersin.org/files/Articles/414841/fpsyt-09-00482-HTML/image_m/fpsyt-09-00482-g001.jpg)
Frontiers | A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers | Psychiatry
![A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC](https://europepmc.org/articles/PMC514842/bin/i1523-5998-6-4-159-f01.jpg)
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC
![Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1043661814000449-fx1.jpg)
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect
![Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues | SpringerLink Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00213-018-4958-9/MediaObjects/213_2018_4958_Fig1_HTML.png)
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues | SpringerLink
![Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190928053113541-0005:S1092852919001470:S1092852919001470_fig4g.jpeg?pub-status=live)
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core
![Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190928053113541-0005:S1092852919001470:S1092852919001470_fig3g.jpeg?pub-status=live)